Universal Biosensors, Inc. (ASX: UBI) is pleased to announce that it has launched its Fructose biosensor test, which is the 4^th test on the Sentia wine testing platform. At the same time UBI has relaunched its Glucose test, which is the partner test used with Fructose to measure Total Residual Sugar during the winemaking process.

Glucose & Fructose are the main fermentable sugars found in wine. They are natural sugars produced in the vines and play a key role in the wine making process. The levels of Glucose & Fructose are important indicators of grape quality and represent the amount of sugar that is available to the yeast for conversion into ethanol.

Glucose & Fructose are monitored at each stage of the wine making process with high glucose levels present during ripening and high fructose levels present in over ripe grapes. These sugars are more closely monitored during the fermentation process as yeast consumes these sugars and converts them into ethanol. The ability to monitor and measure both glucose and fructose concentrations in real time at the barrel side will allow wine makers to more accurately determine an endpoint for fermentation.

Mr John Sharman, CEO of UBI said; “The launch of Fructose & Glucose is a very important achievement for our business and means UBI now has 4 important tests on our wine testing platform (Free SO2, Malic Acid, Glucose & Fructose). We estimate the market for Total Sugars to be more than $160m pa.”

Mr Sharman said; “Whilst we completed work on the Glucose biosensor in the second half of 2022, the measurement of Glucose without Fructose is not meaningful for winemakers and Sentia sales were negatively impacted by the delay of Fructose. Now that we have both Glucose & Fructose available for sale, we are confident the Sentia wine testing platform can deliver strong sales growth during 2023.”

For further information please refer to the Sentia website (www.mysentia.com).

Enquiries:

John Sharman

Chief Executive Officer

+61 (0) 414 440 680

Announcement authorized by the Board of Directors of Universal Biosensors, Inc.

About Universal Biosensors

Universal Biosensors, founded in 2001, specialises in the design and development of electrochemical cells (strips) used in conjunction with point of use devices that are used in various industries such as healthcare (point of care), wine, food, and agriculture. UBI’s ambition is to build a multi product stable of biosensors in large markets which generate ongoing revenue streams. For additional information regarding Universal Biosensors, Inc., refer to: http://www.universalbiosensors.com.

Forward-Looking Statements

The statements contained in this release that are not purely historical are forward-looking statements within the meaning of the US Securities Exchange Act of 1934. Forward-looking statements in this release include statements regarding our expectations, beliefs, hopes, intentions or strategies. All forward-looking statements included in this release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. Our actual results could differ materially from our current expectations. We cannot assure you when, if at all, the proposals outlined in this release will occur, and the terms of any such proposal are subject to change. Factors that could cause or contribute to such differences include, but are not limited to, factors and risks disclosed from time to time in reports filed with the SEC.